Chronic obstructive pulmonary disease will be the third most common cause of death worldwide by 2020 ([@b44-copd-1-31]), and costs the global healthcare system tens of billions of dollars annually. For reasons that are largely unknown, COPD is only marginally responsive to all contemporary drugs, even powerful antiinflammatory glucocorticosteroids ([@b29-copd-1-31]; [@b2-copd-1-31]). COPD is diverse and encompasses emphysema, the proteolytic destruction of alveolar units; bronchitis, associated with massive goblet cell and mucous gland proliferation; and bronchiolitis, an inflammatory condition of small airways associated with fibroblast proliferation and fibrosis. The cause of most COPD is cigarette smoking, but the molecular pathogenesis of COPD is obscure. Inhaled smoke or irritants are thought to trigger alveolar macrophages and the epithelium to secrete tumor necrosis factor-alpha (TNF-α), interleukin 8 (IL-8), and chemokines such as macrophage inflammatory proteins (MIPs). These factors are chemotactic and activating factors for neutrophils, macrophages, and other inflammatory cells. Over time the lung also accumulates increased numbers of CD8+ lymphocytes, which are capable of triggering macrophage-dependent lung proteolysis. Emphysema results from destruction of alveolar units by proteases such as neutrophil elastase (NE; also a potent goblet cell secretagogue), macrophage metalloelastases like MMP-12 ([@b19-copd-1-31]; [@b24-copd-1-31]), and possibly also by apoptosis of alveolar wall cells.

In the small airways, fibroblast proliferation and collagen deposition cause fixed airway obstruction ([@b26-copd-1-31]). The resulting airflow limitation is compounded in many patients by mucus hypersecretion and inflammation. Lung destruction in COPD is well correlated with the intensity of inflammation and once inflammation is established in COPD, removing the provocative stimulus through smoking cessation does not resolve disease ([@b63-copd-1-31]). Furthermore, it is unknown why COPD is associated with a very high prevalence of both viral and bacterial exacerbations (known triggers of the innate immune system, specifically macrophages and natural killer cells), prompting further damage to the lungs. It is believed that much of the deterioration that accompanies exacerbations is due to flaring of inflammation. This interpretation is supported by spikes in inflammatory markers during exacerbations measured in sputum and in breath condensates.

Although there remains much to be understood, our current understanding of molecular pathways in COPD pathogenesis implicates Akt as a central regulator. Akt, (also previously referred to as protein kinase B \[PKB\]), is an intracellular serine/threonine protein kinase that is activated by a broad range of cytokines (eg, TNFα) ([@b43-copd-1-31]), growth factors (eg, PDGF, GM-CSF, CTGF) ([@b31-copd-1-31]; [@b48-copd-1-31]; [@b14-copd-1-31]), and cigarette smoke components, including nicotine ([@b45-copd-1-31]; [@b67-copd-1-31]). In particular, Akt is a major target of PI3-kinase (PI3K) dependent signaling pathways ([Figure 1](#f1-copd-1-31){ref-type="fig"}). On activation, Akt is recruited to membrane associated signaling complexes and activated by phosphorylation. In addition to Akt, PI3K activates multiple signaling kinases (PKC, MAPK, Btk, ILK) involved in key processes. Hence, targeting PI3K directly may be detrimental due to its pleiotropic activities.

There are three known homologs of Akt that display a high level of homology at the amino acid level ([Table 1](#t1-copd-1-31){ref-type="table"}). The most characterized isoform, Akt1, is expressed in various tissues including lung, and targets diverse substrates involved in critical cellular events such as cell survival, proliferation, and transcription.

Hence, the multifunctional activities of Akt have the potential to coordinate cellular mechanisms that are strongly implicated in the destructive pathogenesis of COPD ([Figure 2](#f2-copd-1-31){ref-type="fig"}). As Akt is a serine/threonine kinase it is amenable to selective pharmacological inhibition ([@b22-copd-1-31]).

Rationale for inhibiting Akt activity in COPD
=============================================

Role in cell survival
---------------------

Apoptosis governs the persistence and severity of inflammation. Akt promotes inflammatory cell survival in vivo. More specifically, oxidative stress and/or GM-CSF- mediated activation of Akt enhances cell survival of macrophages, neutrophils, and T lymphocytes ([@b27-copd-1-31]; [@b31-copd-1-31]; [@b66-copd-1-31]). Akt inhibits apoptosis by four main mechanisms: (1) phosphorylation and inactivation of BAD ([@b16-copd-1-31], [@b15-copd-1-31]), which normally binds to and inactivates antiapoptotic Bcl~2~ and Bcl~XL~, a critical step in the activation of the caspase protease pathway. However, since Akt displays pro-survival properties in tissues that do not express detectable levels of BAD, alternative mechanisms must exist. Akt also promotes survival by: (2) phosphorylation of lytic pro-caspase-9 ([@b11-copd-1-31]). This event blocks the activity of pro-caspase-9 by altering the conformation of its substrate-binding pocket, thereby inhibiting apoptosis. Apoptosis can also be induced by expression of key genes involved in cell death. For example, withdrawal of survival factors promotes transcription of the Fas ligand gene involved in positively regulating the caspase protease pathway. Akt controls their expression by: (3) maintaining Forkhead family of transcriptional factors (AFX) in a transcriptionally silent form ([@b3-copd-1-31]; [@b9-copd-1-31]). In the absence of Akt signaling, AFX members are directed to the nucleus where they bind to insulin-responsive sequence (Irs) found in a number of promoters responsible for controlling apoptosis gene expression. When Akt activity is maintained for prolonged periods, Forkhead members are sequestered away from the nucleus by Akt-mediated phosphorylation. Phosphorylated AFX members are kept transcriptionally silent due to a physical interaction with the structural cytoplasmic protein, 14-3-3. (4) More recently, Akt has been shown to promote activation of the transcription factor CREB, which enhances transcription of cell survival genes such as the Bcl-2 family member, Mcl-1 ([@b65-copd-1-31]). Therefore, in a chronically inflamed COPD lung that is constantly exposed to cigarette smoke and airborne pathogens, Akt activity will be maintained for prolonged periods. The persistence of Akt-mediated survival of inflammatory cells may prove to be an integral process responsible for the accumulation of macrophages, neutrophils, and T lymphocytes in the airways, parenchyma, and pulmonary vasculature. A paradox that cannot be explained with current knowledge is that the epithelium and T cells from COPD patients have a somewhat increased rate of apoptosis ([@b25-copd-1-31]). [@b37-copd-1-31] have reported enhanced parenchymal apoptosis in COPD in association with lymphocytic infiltration. The increased rate of apoptosis needs to be balanced against evidence for enhanced proliferation ([@b70-copd-1-31]). [@b60-copd-1-31] found that alveolar macrophage apoptosis was decreased in macrophages from smokers in association with increased p21(Cip/Waf) BCLxL expression. Neutrophil apoptosis is markedly reduced during COPD exacerbations ([@b47-copd-1-31]). It has also been suspected for some time that vascular endothelial cell death may be a pathogenic contributor to the development of emphysema in COPD ([@b28-copd-1-31]).

Role in proliferation
---------------------

Akt may promote in situ macrophage and fibroblast proliferation. Macrophage proliferation in COPD has been recognized for several decades ([@b4-copd-1-31]) notwithstanding recent evidence suggesting increased apoptotic rates. Most in vitro evidence suggests that smoke directly suppresses fibroblast proliferation in COPD but the pattern of growth factor expression in thickened small airways suggests the opposite occurs in vivo. The in vivo response of parenchymal fibroblasts is less certain. Macrophage and fibroblast proliferation in COPD worsens inflammation and promotes airway fibrosis, which leads to fixed obstruction in small airways. Inhaled smoke and pathogen products released during exacerbations cause lung tissue damage, which triggers tissue repair mechanisms releasing multiple growth factors including PDGF, TGFβ, IGF1, EGF, CTGF, and bFGF, all of which activate Akt.

Recently, Akt has been implicated in the regulation of cellular proliferation and cell cycle control, a function more usually associated with MAP kinases. Akt inactivates the cell cycle regulator GSK3 by phosphorylation ([@b52-copd-1-31]), promoting cell cycle entry by targeting D-type cyclins for proteolysis ([@b17-copd-1-31]). Hence, mitogen-induced activation of cyclin D ultimately leads to the G~1~→S transition of the cell cycle. Furthermore, by phosphorylating and inactivating AFX transcription factor, Akt also blocks expression of the cell cycle inhibitor p27^kip1^, whose expression is AFX dependent ([@b41-copd-1-31]). This prevents p27^kip1^ from binding to the cyclinD/CDK2 complex and derepressing cell cycle arrest.

Role in inflammation
--------------------

Akt is directly activated by gram-negative bacterial cell wall lipopolysaccharide (LPS) ([@b7-copd-1-31], [@b6-copd-1-31]) and other innate immunity triggers implicated in COPD exacerbations ([@b50-copd-1-31]). In addition, Akt is activated by oxidative stress, in part via the EGF receptor (EGFR) ([@b66-copd-1-31]), both of which are strongly implicated in COPD ([@b35-copd-1-31]). Akt selectively triggers NF~κ~B p65/RelA heterodimer activation to coordinate monocyte and neutrophil recruitment in response to smoke and infection. The transduction pathways and inflammatory responses activated by cigarette smoke and infectious pathogen products such as LPS trigger innate immunity-mediated exacerbations in a similar manner, as inferred by coordinated expression of chemoattractant factors following activation of NF~κ~B. This is not just because LPS is a biologically active component of cigarette smoke occurring in concentrations known to cause lung disease ([@b23-copd-1-31]). It is also because cigarette smoke consists of multiple components capable of stimulating signal transduction pathways that are similar to those triggered by receptors of the innate immune system. Bacterial endotoxins stimulate lung epithelial cells to release neutrophil and monocyte chemotactic peptides ([@b33-copd-1-31], [@b34-copd-1-31]) by coordinated activation of Toll-like receptors (TLRs) that respond to LPS (gram-negative cell wall component; TLR4) and lipoteichoic acid (gram-positive cell wall component; TLR2) ([@b8-copd-1-31]; [@b57-copd-1-31]; [@b64-copd-1-31]). Consistent with LPS, cigarette smoke extract also promotes release of chemotactic factors ([@b40-copd-1-31]). Binding sites for NF~κ~B are present in the promoter region of many inflammatory mediators including GM-CSF ([@b59-copd-1-31]), MCP-1 ([@b56-copd-1-31]), and IL-8 ([@b46-copd-1-31]); and NF~κ~B cooperates as part of a higher order complex to promote transcription. NF~κ~B is normally sequestered in the cytoplasm through an association with inhibitor of NF~κ~B (I~κ~B). When cells are exposed to activation signals such as LPS, oxidative stresses, and TNFα, I~κ~B is phosphorylated and targeted for proteolytic destruction. This process is promoted by Akt, which triggers I~κ~B kinase alpha (IKKa) to phosphorylate I~κ~B ([@b46-copd-1-31]). Akt can also enhance the DNA binding activity of NF~κ~B by targeting the transactivation domain of the p65 subunit for phosphorylation ([@b53-copd-1-31]; [@b36-copd-1-31]).

Akt, lung cancer, and acquired somatic mutations of the lung epithelium
-----------------------------------------------------------------------

Lung cancer is the most frequent cause of tumor-associated deaths in the US and is strongly associated with chronic smoking. Lung cancer arises from a series of pathological changes linked to both gross genetic alterations and quite discrete acquired gene changes known as somatic mutations. Airflow obstruction is commonly present in patients with bronchial carcinoma ([@b13-copd-1-31]), and the presence of moderate to severe airflow obstruction is a significant predictor of incident lung cancer ([@b38-copd-1-31]). Therefore, a logical and widely accepted corollary is that chronic inflammation predisposes to the development of cancer ([@b39-copd-1-31]). Since the acquisition of somatic mutations predisposes to lung cancer, we have previously proposed that non-inherited genetic abnormalities also contribute to the pathogenesis of COPD ([@b1-copd-1-31]). As only 15% of smokers develop COPD, much recent research has focused on identifying inherited genetic risk factors such as α~1~-antitrypsin deficiency associated with early onset COPD. However, less then 1% of COPD patients display α~1~-antitrypsin deficiencies, and searches for other heritable mutations including TNFα, IL-10, MMPs, and IL-8 have yielded limited success. We have proposed the novel hypothesis that a fundamental determinant of COPD is the acquisition of mutations (caused by mutagens in cigarette smoke) in regulatory oncogenes that control Akt activation status in the epithelium. This hypothesis is supported by cytogenetic studies on the molecular pathogenesis of lung cancer that have unequivocally demonstrated very frequent loss of heterozygosity (LOH) somatic mutations in preneoplastic/dysplastic epithelium of smokers ([@b68-copd-1-31]; [@b69-copd-1-31]).

Indeed it is now apparent that the epithelium can become a mosaic of epithelial lineages, each carrying one or more somatic mutations. Although histological abnormalities in the epithelium associated with smoking can resolve after cessation, these somatic mutations persist as much as inflammation persists in the mucosa of ex-smokers ([@b68-copd-1-31]). Multiple gene mutations appear necessary to develop lung cancer, but single gene loci changes may be sufficient to trigger COPD. Of the known oncogenic mutations in the epithelium, three of the most frequent directly promote Akt activation. These are: (1) oncogenic mutations of Ras (p21); a GTP bound form of Ras interacts with PI3K, that in turn activates Akt. Ras mutations occur in approximately 30% of all human malignancies with a \>30% mutation frequency in the bronchial epithelium of human lung cancer patients ([@b51-copd-1-31]). Ras-transformed adherent epithelial cells display elevated levels of Akt activity, and inhibition of this activity blocks the transforming potential of Ras by inducing cell death ([@b30-copd-1-31]). (2) The lipid phosphatase tumor suppressor PTEN degrades phospholipid products generated by PI3K, thereby negatively regulating the activity of Akt. PTEN is mutated in a large fraction of all human cancers, with a mutation frequency approaching that of p53. More recently, PTEN mutations have been found in 6/15 (40%) of small cell lung carcinomas (SCLC) ([@b32-copd-1-31]). Loss of PTEN activity attributed to homozygous deletions of the PTEN gene correlate with elevated levels of Akt activity, and reconstitution of PTEN restores normal Akt regulation ([@b55-copd-1-31]). (3) A constitutively active form of PI3K has been reported to exist in a small-scale screen of SCLC cell lines. Of the five cell lines tested, all exhibited high basal constitutive PI3K activity, which resulted in elevated basal Akt activity ([@b42-copd-1-31]).

Preneoplastic changes also occur more commonly in smokers and may manifest as a phenotypic abnormality in the bronchial epithelium known as squamous metaplasia. Here, ciliated epithelial cells that normally trap and remove airborne particulates and mucus are replaced by flat, non-ciliated cells. The consequences of this altered phenotype are believed to include airway obstruction mediated by mucus accumulation. In addition, impaired pathogen clearance has been implicated in lower airway bacterial colonization and is prominent in advanced COPD. The mechanism that drives this altered phenotype is obscure and thought to be associated with an ongoing damage/repair cycle triggered by chronic smoking; however, Akt may prove to be an important molecular regulator of this process. Conceptually, sustained activation of Akt in the bronchial epithelium as a consequence of exposure to cigarette smoke favors an ongoing proliferative process that prevents differentiation into normal epithelial cells. Consistent with this hypothesis, nicotine has been shown to modulate the phenotype of normal airway epithelial cells via an Akt dependant mechanism ([@b45-copd-1-31]; [@b67-copd-1-31]).

Rationale for selective restoration of Akt activity in COPD
===========================================================

Akt and apoptosis-mediated emphysema
------------------------------------

The long-standing paradigm for alveolar septal wall destruction in emphysema involves an imbalance between proteases and antiproteases that results in digestion of elastin and other structural proteins. However, alternate mechanisms may also exist as alveolar matrix destruction is not prevalent in cystic fibrosis, acute asthma, and other lung diseases associated with excessive inflammation and proteolysis. A recent model for the loss of lung tissue in emphysema implicates enhanced apoptosis as supported by animal models and a small number of human studies. Targeting disruption of vascular endothelial growth factor (VEGF) in mice results in increased alveolar and bronchial cell apoptosis, airspace enlargement, and persistent changes in lung elastic recoil ([@b61-copd-1-31], [@b62-copd-1-31]; [@b58-copd-1-31]). Akt plays a critical role in VEGF-mediated cell survival ([@b20-copd-1-31]) and, hence, would most likely prevent apoptosis in VEGF depleted lungs, although this hypothesis has yet to be tested. Even though these findings are quite striking in animal models, the role of VEGF in human COPD disease has not been clearly established. Despite there being no strong evidence implicating a defect in VEGF expression in emphysema, oxidative stress has been shown to impair VEGF survival signaling via inhibition of PI3K/Akt ([@b18-copd-1-31]). More recently, marked alveolar apoptosis has been observed in end-stage emphysema patients ([@b70-copd-1-31]; [@b10-copd-1-31]). Selective restoration of Akt in VEGF dependent endothelial lung cells would therefore prevent accelerated alveolar apoptosis associated with cellular destruction in emphysema.

Akt and muscle wasting in COPD
------------------------------

COPD elicits a persistent local inflammatory process that has quite marked peripheral consequences such as the wasting syndrome seen in advanced COPD. In COPD, even clinically obese patients have loss of lean muscle mass identified on MRI imaging. Locally, cytokines such as IL-6, TNFα, and IL-1β are released in chronically inflamed COPD lungs, which can act on multiple organ systems, tissues, and cell types. Such inflammatory cytokines are known to impair activity of anabolic hormones such as insulin growth factor-1 (IGF-1) ([@b54-copd-1-31]). Akt is activated by IGF-1, an important mediator of signaling programs in skeletal muscle. For instance, increasing Akt activation has the potential to induce hypertrophic pathways while repressing atrophic processes ([@b5-copd-1-31]; [@b49-copd-1-31]). Akt promotes skeletal muscle hypertrophy via a number of downstream signaling pathways; direct and indirect targets include the mammalian target of rapamycin (mTOR), p70 S6 kinase (p70^S6K^), PHAS-1 (4EBP-1), and glycogen synthase kinase 3β ([@b21-copd-1-31]). Reduced IGF-1 expression is observed in most wasting syndromes ([@b54-copd-1-31]), which will impact on Akt activity in muscle tissue. In rodents, selective overexpression of Akt1 in skeletal muscle cells causes hypertrophy and protects against denervation-induced atrophy, while mice with genetically disrupted Akt1 display growth defects ([@b12-copd-1-31]). Thus, the IGF-1/Akt signaling pathway provides a potential therapeutic target for promoting muscle hypertrophy in chronic diseases where wasting manifests. However, since Akt is ubiquitously expressed and promotes cell survival, proliferation, and inflammation, selective targeting of Akt in affected tissue would be most efficacious.

Summary
=======

COPD is a heterogenous disease that is pathologically diverse, complex in nature, and is associated with defects in cell growth, survival, and inflammation. Consequently, developing an effective therapeutic strategy is difficult as multiple cellular processes need to be targeted. Dysregulation of Akt activity will impact on all these essential cellular processes, therefore implicating Akt as an attractive therapeutic target. The strategy of modulating Akt activity will develop as our understanding of COPD pathogenesis progresses, since there is evidence for either inhibiting or restoring Akt activity. The significance of Akt will become more apparent as we evolve a better understanding of the cellular processes that drive the altered phenotype that leads to reduced lung function. The challenge that lies ahead is that of generating highly specific therapies that either block or restore Akt activity in discrete tissue compartments.

![Ligand-targeted activation of Akt. Ligand-mediated activation of a broad range of receptors promotes recruitment of PI3K (p85 and p110 complex) to the plasma membrane, where this lipid kinase catalyzes the production of phosphatidylinositol-3,4,5-phosphate (PtIn3,4,5)-P. PTEN (lipid phosphatase) limits this reaction by reverting PtIns(3,4,5)-P to PtIns(3,4)-P. This phospholipid acts as a docking molecule for both Akt and its activator PDK-1, which activates Akt by direct phosphorylation of the critical T(activation)-loop residue (Thr-308). Once active, Akt is released from the membrane to target multiple cellular substrates and is subsequently inactivated by protein phosphatase2A (PP2A) dephosphorylation.](copd-1-31f1){#f1-copd-1-31}

![Akt is a molecular mediator of cellular processes central to COPD pathogenesis. Cell surface receptors on alveolar macrophages and the bronchial epithelium recognize and respond to cigarette smoke components and respiratory pathogens. These unique signaling modules converge onto and activate multiple pathways including Akt. Once active, Akt contributes to key cellular processes including proliferation, apoptosis, and inflammation. Therefore, dysregulated activation of Akt in a chronically inflamed environment has the potential to disrupt homeostasis, leading to an altered pathology responsible for dramatic and progressive decline in lung function.](copd-1-31f2){#f2-copd-1-31}
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Mammalian Akt homologs

  Isoform   Homology to Akt1   Distribution
  --------- ------------------ ---------------------------------------------------------------
  Akt1      100%               Ubiquitous
  Akt 2     90%                Prominent in heart, liver, muscle, kidney, and adipose tissue
  Akt 3     83%                Prominent in brain, kidney, lung, testis
